Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify® Mutation Profiler.
Pepe F, Russo G, Barraco N, Bono M, Listì A, Righi L, de Biase D, Maloberti T, Scimone C, Palumbo L, Rocco D, Roscigno G, Gallo E, Buglioni S, Coco M, Muscarella LA, Troncone G, Malapelle U. Pepe F, et al. Among authors: barraco n. Oncol Ther. 2024 Nov 28. doi: 10.1007/s40487-024-00316-0. Online ahead of print. Oncol Ther. 2024. PMID: 39607606 Free article.
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints.
Fanale D, Corsini LR, Bono M, Randazzo U, Barraco N, Brando C, Cancelliere D, Contino S, Giurintano A, Magrin L, Pedone E, Perez A, Piraino P, Pivetti A, Giovanni ED, Russo TDB, Prestifilippo O, Gennusa V, Pantuso G, Russo A, Bazan V. Fanale D, et al. Among authors: barraco n. Crit Rev Oncol Hematol. 2024 Jan;193:104220. doi: 10.1016/j.critrevonc.2023.104220. Epub 2023 Nov 29. Crit Rev Oncol Hematol. 2024. PMID: 38036154 Review.
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
Incorvaia L, Perez A, Marchetti C, Brando C, Gristina V, Cancelliere D, Pivetti A, Contino S, Di Giovanni E, Barraco N, Bono M, Giurintano A, Bazan Russo TD, Gottardo A, Cutaia S, Pedone E, Peri M, Corsini LR, Fanale D, Galvano A, Scambia G, Badalamenti G, Russo A, Bazan V. Incorvaia L, et al. Among authors: barraco n. Cancer Treat Rev. 2023 Dec;121:102650. doi: 10.1016/j.ctrv.2023.102650. Epub 2023 Oct 31. Cancer Treat Rev. 2023. PMID: 37939446 Free article. Review.
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier?
Gristina V, Pisapia P, Barraco N, Pepe F, Iacono F, La Mantia M, Peri M, Galvano A, Incorvaia L, Badalamenti G, Bazan V, Troncone G, Russo A, Malapelle U. Gristina V, et al. Among authors: barraco n. Expert Rev Mol Diagn. 2023 Jul-Dec;23(10):851-861. doi: 10.1080/14737159.2023.2245752. Epub 2023 Aug 8. Expert Rev Mol Diagn. 2023. PMID: 37552548 Review.
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study.
Incorvaia L, De Biase D, Nannini M, Fumagalli E, Vincenzi B, De Luca I, Brando C, Perez A, Pantaleo MA, Gasperoni S, D'Ambrosio L, Grignani G, Maloberti T, Pedone E, Bazan Russo TD, Mazzocca A, Algeri L, Dimino A, Barraco N, Serino R, Gristina V, Galvano A, Bazan V, Russo A, Badalamenti G. Incorvaia L, et al. Among authors: barraco n. Oncologist. 2024 Jan 5;29(1):e141-e151. doi: 10.1093/oncolo/oyad206. Oncologist. 2024. PMID: 37463014 Free PMC article.
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay.
Incorvaia L, Rinaldi G, Badalamenti G, Cucinella A, Brando C, Madonia G, Fiorino A, Pipitone A, Perez A, Li Pomi F, Galvano A, Gristina V, Barraco N, Bono M, Bazan Russo TD, Toia F, Cordova A, Fanale D, Russo A, Bazan V. Incorvaia L, et al. Among authors: barraco n. Ther Adv Med Oncol. 2023 Feb 15;15:17588359231151845. doi: 10.1177/17588359231151845. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36818688 Free PMC article.
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors.
Dimino A, Brando C, Algeri L, Gristina V, Pedone E, Peri M, Perez A, De Luca I, Sciacchitano R, Magrin L, Bazan Russo TD, Bono M, Barraco N, Contino S, La Mantia M, Galvano A, Badalamenti G, Russo A, Bazan V, Incorvaia L. Dimino A, et al. Among authors: barraco n. Cancers (Basel). 2022 Dec 29;15(1):216. doi: 10.3390/cancers15010216. Cancers (Basel). 2022. PMID: 36612211 Free PMC article. Review.
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible.
Gristina V, La Mantia M, Peri M, Iacono F, Barraco N, Perez A, Viscardi G, Cutaia S, Russo TDB, Anwar Z, Incorvaia L, Fulfaro F, Vieni S, Pantuso G, Graceffa G, Russo A, Galvano A, Bazan V. Gristina V, et al. Among authors: barraco n. Crit Rev Oncol Hematol. 2023 Feb;182:103899. doi: 10.1016/j.critrevonc.2022.103899. Epub 2022 Dec 31. Crit Rev Oncol Hematol. 2023. PMID: 36596401 Free article. Review.
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study.
Gristina V, Barraco N, La Mantia M, Castellana L, Insalaco L, Bono M, Perez A, Sardo D, Inguglia S, Iacono F, Cutaia S, Bazan Russo TD, Francini E, Incorvaia L, Badalamenti G, Russo A, Galvano A, Bazan V. Gristina V, et al. Among authors: barraco n. Cancers (Basel). 2022 Dec 6;14(23):6013. doi: 10.3390/cancers14236013. Cancers (Basel). 2022. PMID: 36497493 Free PMC article.
41 results